HTGC Stock Recent News

In the most recent trading session, Hercules Capital (HTGC) closed at $17.54, indicating a +1.8% shift from the previous trading day.

SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that it has scheduled its first quarter 2025 financial results conference call for Thursday, May 1, 2025, at 2:00 p.m. PT (5:00 p.m. ET). Hercules will release its financial.

SAN MATEO, Calif.--(BUSINESS WIRE)--This press release corrects, replaces and entirely supersedes a prior version published on April 16, 2025. Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that Fitch Ratings, Inc. (“Fitch”) has upgraded Hercules' senior s.

SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that Fitch Ratings, Inc. (“Fitch”) has upgraded Hercules' investment grade credit and corporate rating to BBB from BBB- with a stable outlook, as well as its underlying anal.

Market volatility due to new tariffs has created a buying window for high-quality BDCs like Hercules Capital, offering a 10% dividend yield. Hercules Capital's strong performance in 2024, with record gross fundings and growing portfolio, positions it well for future growth in the VC-backed tech sector. Despite being the most expensive BDC, Hercules Capital's solid dividend coverage, supplemental dividends, and growth catalysts justify its high NAV premium.

We take a look at the action in business development companies through the first week of April and highlight some of the key themes we are watching. BDCs faced significant losses, with average returns around -9% on the week with valuations dropping below historical averages. Valuation uncertainty is high due to quarterly NAV declarations and systemic/idiosyncratic factors; estimated NAV drops are 2-3% from Q4 levels.

In the most recent trading session, Hercules Capital (HTGC) closed at $16.83, indicating no shift from the previous trading day.

Zug, Switzerland, April 3, 2025 – MoonLake Immunotherapeutics (MoonLake; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced that it has entered into an agreement with Hercules Capital, Inc. (NYSE:HTGC), a leader in customized debt financing for companies in the life sciences and technology-related markets, for up to $500 million in non-dilutive capital, of which $75 million drawn down at close and additional tranches will become available upon achievement of certain pre-specified milestones that are aligned with MoonLake's strategy and funding needs.

Hercules Capital (HTGC) closed at $19.06 in the latest trading session, marking a -0.21% move from the prior day.

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has entered into a loan and security agreement with Hercules Capital, Inc. (NYSE: HTGC), for up to $200 million. Access to the additional capital strengthens Savara's balance sheet following the submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a tre.